An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-16
DOI
10.1038/s41598-020-71519-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
- (2020) Mohamed A. ElTanbouly et al. SCIENCE
- Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation
- (2019) Nishant Mehta et al. Cell Reports
- VISTA is an acidic pH-selective ligand for PSGL-1
- (2019) Robert J. Johnston et al. NATURE
- The Significant Value of Preoperative Prognostic Nutritional Index for Survival in Pancreatic Cancers
- (2018) Jiandong Liu et al. PANCREAS
- Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
- (2018) Shan Xie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
- (2017) Megan Lo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening
- (2017) Wei Yang et al. JOURNAL OF BIOTECHNOLOGY
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
- (2014) Dallas B. Flies et al. JOURNAL OF CLINICAL INVESTIGATION
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Beyond natural antibodies: the power of in vitro display technologies
- (2011) Andrew R M Bradbury et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now